Overview of potential oncomarkers for detection of early stages of ovarian cancer;Prehl'ad potenciálnych onkomarkerov detekcie skorých fáz rakoviny vaječníkov

Klinicka Onkologie

Volumn 24, Issue 2, 2011, Pages 106-111

  Urban, Peter ^a   Bilecova Rabajdova M ^a   Stefekova Z ^a   Ostro A ^a   Marekova M ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Biochemical tumor markers; Molecular diagnostics; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; DEATH RECEPTOR; DEATH RECEPTOR 6; GLYCOPROTEIN; GLYCOPROTEIN M6B; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; BLOOD CHEMISTRY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; EARLY CANCER; GENE IDENTIFICATION; GENETIC PREDISPOSITION; HUMAN; METASTASIS; MOLECULAR BIOLOGY; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; WOMEN'S HEALTH;

EID: 79955559945     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Fiorca JV, Roberts WS. Screening for Ovarian Cancer. Cancer Control 1996; 3(2): 120-129. (Pubitemid 26162154)
2. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68(4): 820-823
3. Cavenee WK, Dryja TP, Phillips RA et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305(5937): 779-784. (Pubitemid 13010953)
4. Gallion HH, Powell DE, Smith LW et al. Chromosome abnormalities in human epithelial ovarian malignancies. Gynecol Oncol 1990; 38(3): 473-477.
5. Berchuck A, Boente MP, Kerns BJ et al. Ploidy analysis of epithelial ovarian cancers using image cytometry Gynecol Oncol 1992; 44(1): 61-65.
6. Thompson FH, Liu Y, Emerson J et al. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. Genes Chromosomes Cancer 1994; 10(4): 262-266. (Pubitemid 24238434)
7. Anttila MA, Ji H, Juhola MT et al. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 1999; 18(1): 42-51. (Pubitemid 29028843)
8. Berchuk A, Kohler MF, Hopkins MP et al. Overexpression of p53 is not a feature of benign and early-stage borderline ovarian tumors Gynecol Oncol 1994; 52(2): 232-236. (Pubitemid 24064376)
9. Wertheim I, Muto MG, Welch WR et al. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86(20): 1549-1551. (Pubitemid 24330221)
10. McManus DT, Murphy M, Arthur K et al. p53 mutation, allele loss on chromosome 17p and DNA content in ovarian carcinoma. J Pathol 1996; 179(2): 177-182. (Pubitemid 26201586)
11. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250(4988): 1684-1689. (Pubitemid 120031871)
12. Narod SA, Feunteun J, Lynch HT et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338(8759): 82-83.
13. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Eng J Med 1988; 319(9): 525-532.
14. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3): 676-689. (Pubitemid 28164626)
15. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11(2): 198-200.
16. Gayther SA, Warren W, Mazoyer S t al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995, 11(4): 428-433.
17. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265(5181): 2088-2090.
18. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12(3): 333-337. (Pubitemid 26080098)
19. Sharan SK, Bradley A. Murine BRCA2: sequence, map position, and expression pattern. Genomics 1997; 40(2): 234-241. (Pubitemid 27124084)
20. Holt JT, Thompson ME, Szabo C et al. Growth retardation and tumor inhibition by BRCA1. Nat Genet 1996; 12(3) 298-302. (Pubitemid 26080089)
21. Scully R, Chen J, Plug A et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88(2): 265-275. (Pubitemid 28015875)
22. Bast RC Jr, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68(5): 1331-1337. (Pubitemid 12235035)
23. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309(15): 883-887. (Pubitemid 13014028)
24. Woolas RP, Oram DH, Jeyarajah AR et al. Ovarian cancer identified through screening with serum markers but not by pelvic imaging Int J Gynecol Cancer 1999; 9(6): 497-501. (Pubitemid 30027555)
25. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22(2): 184-204. (Pubitemid 32458158)
26. Diamandis EP, Scorilas A, Fracchioli S et al. Human kallikrein 6 (hK6) a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21(6): 1035-1043 (Pubitemid 46594132)
27. Luo LY, Katsaros D, Scorilas A et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003; 63(4): 807-811. (Pubitemid 36231980)
28. Diamandis EP, Okui A, Mitsui S et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002, 62(1): 295-300. (Pubitemid 34074018)
29. Shridhar V, Sen A, Chien J et al. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 2002; 62(1): 262-270. (Pubitemid 34074013)
30. Schaner ME, Ross DT, Ciaravino G et ai. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14(11): 4376-4386. (Pubitemid 37444641)
31. Spentzos D, Levine DA, Ramoni MF et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22(23): 4700-4710.
32. Donninger H, Bonome T, Radonovich M et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23(49): 8065-8077.
33. Takahashi T, Nau MM, Chiba I et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246(4929): 491-494. (Pubitemid 19273938)
34. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359(9306): 572-577. (Pubitemid 34178440)
35. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64(16): 5882-5890.
36. Bartlett JM. Ovarian Cancer: Methods and Protocols, Methods in Molecular Medicine. Totowa, New Jersey: Humana Press 2000.
37. Bayani J, Brenton JD, Macgregor PF et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 2002; 62(12): 3466-3476. (Pubitemid 34651394)
38. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures Cancer Res 2001; 61(20): 7388-7393. (Pubitemid 32995021)
39. Feng H, Ghazizadeh M, Konishi H et al. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002; 32(12): 525-529. (Pubitemid 43102758)
40. Giacona MB, Ruben GC, Iczkowski KA et al. Cell-free DNA in human blood plasma length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17(1): 89-97. (Pubitemid 28293013)
41. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence of their origin from apoptotic and necrotic cells. Cancer Res 2001; 61(4): 1659-1665. (Pubitemid 34292602)
42. Sorenson GD, Pribish DM, Valone FH et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994; 3(1): 67-71.
43. Sorenson GD. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000, 6(6): 2129-2137. (Pubitemid 30399177)
44. Anker P, Mulcahy H, Chen XQ et al. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18(1): 65-73. (Pubitemid 29411092)
45. Bussink AP, Speijer D, Aerts JM et al. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 2007; 177(2): 959-970. (Pubitemid 350005647)
46. Johansen JS, Jensen BV, Roslind A et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006; 15(2): 194-202. (Pubitemid 43342164)
47. Yamac D, Ozturk B, Coskun U et al. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008; 25(8): 801-809.
48. Roslind A, Knoop AS, Jensen MB et al. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008; 112(2): 275-285.
49. Lau SH, Sham JS, Xie D et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006; 25(8): 1242-1250
50. Mitsuhashi A, Matsui H, Usui H et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009; 20(1): 71-77.
51. Kucur M, Isman FK, Balci C et al. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol 2008; 26(1): 47-52.
52. Bamberger ES, Perrett CW Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002; 55(6): 348-359. (Pubitemid 35454510)
53. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006; 33(2 Suppl 6): S3-S11.
54. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science 2000; 289(5482): 1197-1202. (Pubitemid 30650733)
55. Seaman S, Stevens J, Yang MY et al. Genes that distinguish physiological and pathological angiogenesis Cancer Cell 2007; 11(6): 539-554. (Pubitemid 46856908)
56. MacFadyen JR, Haworth O, Roberston D et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005; 579(12): 2569-2575. (Pubitemid 40615660)
57. Conejo-Garcia JR, Benencia F, Courreges MC et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10(9): 950-958. (Pubitemid 39273736)
58. Conejo-Garcia JR, Buckanovich RJ, Benencia F. Vascular leukocytes contribute to tumor vascularization. Blood 2005; 105(2): 679-681. (Pubitemid 40070752)
59. Lu C, Bonome T, Li Y et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67(4): 1757-1768. (Pubitemid 46383403)
60. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25(7): 852-861. (Pubitemid 350002886)
61. Baichwal VR, Baeuerle PA. Activate NF-kappa B or die? Curr Biol 1997; 7(2): R94-R96.
62. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins activation, costimulation, and death Cell 1994; 76(6): 959-962. (Pubitemid 24106376)
63. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390(6656): 175-179. (Pubitemid 27507987)
64. Pan G, O'Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL Science 1997; 276(5309): 111-113.